多支血管PCI在伴心源性休克的STEMI患者中的应用
该研究基于韩国KAMIR-NIH前瞻性多中心注册数据,纳入659例伴心源性休克的STEMI多支血管病变患者,比较多支血管PCI与仅处理罪犯血管PCI的预后。结果显示多支血管PCI组1年全因死亡风险显著低于仅IRA组(21.3% vs 31.7%,HR 0.59,95%CI 0.43-0.82,p=0.001),非IRA重复血运重建风险也更低。
要点
- 伴心源性休克的STEMI多支病变患者中,多支血管PCI与1年全因死亡风险降低相关。
- 多支血管PCI组非IRA重复血运重建风险显著低于仅IRA-PCI组。
- 多支血管完全血运重建可能是改善此类高危患者预后的合理策略。
核心结论
- 在伴心源性休克的STEMI多支血管病变患者中,多支血管PCI与1年全因死亡和非IRA重复血运重建风险显著降低相关。
研究设计与样本
- 基于韩国KAMIR-NIH前瞻性多中心注册研究,从13,104例连续患者中筛选出伴心源性休克并接受直接PCI的STEMI多支血管病变患者,共659例,其中多支血管PCI组260例,仅IRA-PCI组399例。
主要发现
- 多支血管PCI组1年全因死亡率为21.3%,仅IRA-PCI组为31.7%(HR 0.59,95%CI 0.43-0.82,p=0.001)。
- 多支血管PCI组非IRA重复血运重建率为6.7%,仅IRA-PCI组为8.2%(HR 0.39,95%CI 0.17-0.90,p=0.028)。
- 经多因素回归、倾向性评分匹配和逆概率加权调整基线差异后,结果一致。
- 在多因素模型中,多支血管PCI与1年全因死亡和患者导向复合终点风险降低独立相关。
临床怎么用
- 对于伴心源性休克的STEMI多支血管病变患者,可考虑行多支血管PCI以实现完全血运重建以改善预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent trials demonstrated a benefit of multivessel percutaneous coronary intervention (PCI) for noninfarct-related artery (non-IRA) stenosis over IRA-only PCI in patients with ST-segment elevation myocardial infarction (STEMI) multivessel disease. However, evidence is limited in patients with cardiogenic shock. OBJECTIVES: This study investigated the prognostic impact of multivessel PCI in patients with STEMI multivessel disease presenting with cardiogenic shock, using the nationwide, multicenter, prospective KAMIR-NIH (Korea Acute Myocardial Infarction-National Institutes of Health) registry. METHODS: Among 13,104 consecutive patients enrolled in the KAMIR-NIH registry, we selected patients with STEMI with multivessel disease presenting with cardiogenic shock and who underwent primary PCI. Primary outcome was 1-year all-cause death, and secondary outcomes included patient-oriented composite outcome (a composite of all-cause death, any myocardial infarction, and any repeat revascularization) and its individual components. RESULTS: A total of 659 patients were treated by multivessel PCI (n = 260) or IRA-only PCI (n = 399) strategy. The risk of all-cause death and non-IRA repeat revascularization was significantly lower in the multivessel PCI group than in the IRA-only PCI group (21.3% vs. 31.7%; hazard ratio: 0.59; 95% confidence interval: 0.43 to 0.82; p = 0.001; and 6.7% vs. 8.2%; hazard ratio: 0.39; 95% confidence interval: 0.17 to 0.90; p = 0.028, respectively). Results were consistent after multivariable regression, propensity-score matching, and inverse probability weighting to adjust for baseline differences. In a multivariable model, multivessel PCI was independently associated with reduced risk of 1-year all-cause death and patient-oriented composite outcome. CONCLUSIONS: Of patients with STEMI and multivessel disease with cardiogenic shock, multivessel PCI was associated with a significantly lower risk of all-cause death and non-IRA repeat revascularization. Our data suggest that multivessel PCI for complete revascularization is a reasonable strategy to improve outcomes in patients with STEMI with cardiogenic shock.
引用
- Lee JM, Rhee TM, Hahn JY, et al. Multivessel Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction With Cardiogenic Shock. J Am Coll Cardiol. 2018. PMID: 29471935. doi:10.1016/j.jacc.2017.12.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。